Immunicom to Present at Immuno-Oncology Investment Conference During ASCO
SAN DIEGO, May 3, 2019 /PRNewswire/ -- Immunicom, Inc., a medical technology company that has been awarded FDA Breakthrough Device Designation for its non-pharmaceutical solution for treating stage IV metastatic cancer will be joining global industry leaders during the 5th Annual Immuno-Oncology Investment Forum on May 31st at the Waldorf Astoria Hotel in Chicago, Illinois. Immunicom's Founder and CEO, Amir Jafri, will present on Immunicom's technology, commercial strategy, global clinical trials, future products pipeline, and revenue projections. Additional information on the event can be found on the conference website.
"We are excited to be presenting at this immuno-oncology conference and attending the 55th annual American Society of Clinical Oncology (ASCO) Meeting, where principle investigators from some of our global clinical trial sites will be meeting face-to-face for the first time," said Mr. Jafri. ASCO's annual meeting is the world's largest clinical cancer research conference, with more than 32,000 oncology professionals attending in 2018, 46% of which were from outside the United States.
Immunicom, Inc. is a privately-held medical technology company located in San Diego, CA focused on developing innovative, non-pharmaceutical approaches for treating cancer, inflammatory diseases, and autoimmune diseases. Immunicom's revolutionary blood-filtering technology has the potential to effectively treat a wide variety of cancer types including those that have not responded to other treatment strategies with possibly fewer side effects than traditional drug and biological-based immunotherapy options. The company seeks to leverage its technology to address unmet medical needs and improve patient access and affordability of cancer and other inflammatory and autoimmune disease treatments around the world.
This press release may contain certain forward-looking statements regarding Immunicom products, technological capabilities, and future business aspirations. All such statements are based upon current Immunicom expectations and involve a number of business and technical risks and uncertainties that could cause actual results to differ materially from anticipated results described, implied or projected in any forward-looking statement, including, without limitation, clinical trial results, regulatory approvals, unexpected changes in technologies, uncertainties inherent in product development and commercialization, intellectual property protection, and the ability of our products to gain market acceptance.
For Additional Information Contact:
Chief Commercial Officer
SOURCE Immunicom, Inc.